JPWO2022192598A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022192598A5 JPWO2022192598A5 JP2023555557A JP2023555557A JPWO2022192598A5 JP WO2022192598 A5 JPWO2022192598 A5 JP WO2022192598A5 JP 2023555557 A JP2023555557 A JP 2023555557A JP 2023555557 A JP2023555557 A JP 2023555557A JP WO2022192598 A5 JPWO2022192598 A5 JP WO2022192598A5
- Authority
- JP
- Japan
- Prior art keywords
- heterocycloalkyl
- cycloalkyl
- alkyl
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 376
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 210
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 177
- 125000000217 alkyl group Chemical group 0.000 claims description 169
- 125000003118 aryl group Chemical group 0.000 claims description 162
- 125000001072 heteroaryl group Chemical group 0.000 claims description 142
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 126
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 124
- 229910052799 carbon Inorganic materials 0.000 claims description 97
- 229910052739 hydrogen Inorganic materials 0.000 claims description 95
- 239000001257 hydrogen Substances 0.000 claims description 79
- 150000001875 compounds Chemical class 0.000 claims description 70
- 150000002431 hydrogen Chemical class 0.000 claims description 67
- 229910052757 nitrogen Inorganic materials 0.000 claims description 67
- 150000003839 salts Chemical class 0.000 claims description 65
- 239000012453 solvate Substances 0.000 claims description 65
- 229910052736 halogen Inorganic materials 0.000 claims description 61
- 150000002367 halogens Chemical class 0.000 claims description 61
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 41
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 27
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims description 24
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 8
- 230000036039 immunity Effects 0.000 claims description 6
- 101001135572 Homo sapiens Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 claims description 5
- 102100033141 Tyrosine-protein phosphatase non-receptor type 2 Human genes 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000002222 downregulating effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 10
- 125000002947 alkylene group Chemical group 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000007969 cellular immunity Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163159966P | 2021-03-11 | 2021-03-11 | |
| US63/159,966 | 2021-03-11 | ||
| PCT/US2022/019840 WO2022192598A1 (en) | 2021-03-11 | 2022-03-10 | Heterocycles and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024509962A JP2024509962A (ja) | 2024-03-05 |
| JPWO2022192598A5 true JPWO2022192598A5 (https=) | 2025-03-05 |
| JP2024509962A5 JP2024509962A5 (https=) | 2025-03-05 |
Family
ID=83227103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023555557A Pending JP2024509962A (ja) | 2021-03-11 | 2022-03-10 | 複素環及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240166641A1 (https=) |
| EP (1) | EP4305030A4 (https=) |
| JP (1) | JP2024509962A (https=) |
| CN (1) | CN117279913A (https=) |
| AU (1) | AU2022234402A1 (https=) |
| CA (1) | CA3211545A1 (https=) |
| WO (1) | WO2022192598A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119137117A (zh) * | 2022-02-02 | 2024-12-13 | 耐瑞欧医疗公司 | 蛋白酪氨酸磷酸酶抑制剂及其用途 |
| US20250134882A1 (en) * | 2022-02-02 | 2025-05-01 | Nerio Therapeutics, Inc. | Protein tyrosine phosphatase inhibitors and uses thereof |
| JP2025530135A (ja) * | 2022-09-13 | 2025-09-11 | カムクワット バイオサイエンシーズ インコーポレイテッド | ベンゾ縮合ｎ－複素環及びその使用 |
| WO2024067802A1 (zh) * | 2022-09-30 | 2024-04-04 | 深圳众格生物科技有限公司 | 蛋白酪氨酸磷酸酶抑制剂及其制备方法和医药用途 |
| JP2025538169A (ja) * | 2022-11-09 | 2025-11-26 | ブリストル－マイヤーズ スクイブ カンパニー | がん疾患を治療するための、タンパク質チロシンホスファターゼ（ｐｔｐｎ２）の阻害剤としての、インダゾール置換１，２，５－チアジアゾリジン誘導体 |
| WO2024141015A1 (en) * | 2022-12-30 | 2024-07-04 | Insilico Medicine Ip Limited | Protein tyrosine phosphatase inhibitors and uses thereof |
| CN120981456A (zh) | 2023-05-24 | 2025-11-18 | 金橘生物科技公司 | 杂环化合物及其用途 |
| AU2024288616A1 (en) * | 2023-07-11 | 2026-02-12 | Shenzhen Zhongge Biological Technology Co., Ltd. | Protein tyrosine phosphatase inhibitor, composition comprising same, and medical use thereof |
| KR20260040037A (ko) | 2023-07-14 | 2026-03-23 | 카톨리에케 유니버시테이트 루벤 | 암 및 대사 질병의 치료를 위한 신규 화합물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL164262A0 (en) * | 2002-04-03 | 2005-12-18 | Novartis Ag | 5-Substituted 1,1-dioxo-1,2,5-thiazolidine-3-one derivatives as ptpase 1b inhibitors |
| UA94724C2 (en) * | 2005-12-08 | 2011-06-10 | Новартис Аг | Thiadiazolidinone derivatives as antidiabetic agents |
| UA94921C2 (en) * | 2005-12-08 | 2011-06-25 | Новартис Аг | 1-orthofluorophenyl substituted 1, 2, 5-thiazolidinedione derivatives as ptp-as inhibitors |
| US9977024B2 (en) * | 2012-12-09 | 2018-05-22 | The Scripps Research Institute | Targeted covalent probes and inhibitors of proteins containing redox-sensitive cysteines |
| US10227356B2 (en) * | 2015-04-20 | 2019-03-12 | Phusis Therapeutics, Inc. | Compounds, compositions and methods for inhibiting CNKSR1 |
| PE20252767A1 (es) * | 2019-03-14 | 2025-12-22 | Calico Life Sciences Llc | Inhibidores de la proteina tirosina fosfatasa y metodos para usarlos |
| CA3191842A1 (en) * | 2020-09-11 | 2022-03-17 | Calico Life Sciences Llc | Protein tyrosine phosphatase inhibitors and methods of use thereof |
-
2022
- 2022-03-10 CN CN202280034468.5A patent/CN117279913A/zh active Pending
- 2022-03-10 JP JP2023555557A patent/JP2024509962A/ja active Pending
- 2022-03-10 CA CA3211545A patent/CA3211545A1/en active Pending
- 2022-03-10 WO PCT/US2022/019840 patent/WO2022192598A1/en not_active Ceased
- 2022-03-10 AU AU2022234402A patent/AU2022234402A1/en active Pending
- 2022-03-10 EP EP22768027.9A patent/EP4305030A4/en active Pending
-
2023
- 2023-09-07 US US18/463,134 patent/US20240166641A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017382405B2 (en) | Compositions and methods for inhibiting arginase activity | |
| AU2022203703A1 (en) | Compositions and methods for inhibiting arginase activity | |
| KR102942565B1 (ko) | Tlr7/8 안타고니스트 및 이의 용도 | |
| JP2011509259A5 (https=) | ||
| JP2022116244A (ja) | Ｐｄ－１／ｐｄ－ｌ１阻害剤 | |
| JP2931344B2 (ja) | 哺乳動物における内毒素シヨツクの治療方法 | |
| JPWO2020033828A5 (https=) | ||
| JP2021534124A5 (https=) | ||
| JPWO2022192598A5 (https=) | ||
| AU2017363299B2 (en) | Method of treating focal segmental glomerulosclerosis | |
| RU2002129354A (ru) | Производные этилендиамина | |
| JP2019510832A (ja) | Ｐｄ−１阻害剤又はｐｄ−ｌ１阻害剤と組み合わせてｃｃｒ１アンタゴニストを投与することによる腫瘍負荷の低減 | |
| RU2713653C2 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ ИНГИБИТОРАМИ С-С ХЕМОКИНОВОГО РЕЦЕПТОРА 9 (CCR9) И АНТИТЕЛАМИ, БЛОКИРУЮЩИМИ α4β7-ИНТЕГРИН | |
| AU2015213344A1 (en) | Novel CC-1065 analogs and their conjugates | |
| JP2006507265A5 (https=) | ||
| CN107406412A (zh) | TGF‑β抑制剂 | |
| RU2009117642A (ru) | Применение спирооксиндоловых соединений в качестве терапевтических средств | |
| AU2022348938A1 (en) | Imidazopyridazine il-17 inhibitor compounds | |
| RU2323211C2 (ru) | Новые производные бензимидазола, способы их получения, их применение и содержащая их фармацевтическая композиция | |
| KR20230012535A (ko) | Enpp1 조절제 및 이의 용도 | |
| EP4291188A1 (en) | Inhibitors of cgas activity as therapeutic agents | |
| JP2025504379A (ja) | 重水素濃縮ピペリジニル－メチル－プリンアミン及び関連化合物、ならびに疾患及び状態の治療におけるそれらの使用 | |
| JP2002537284A (ja) | メビノリン誘導体 | |
| JP2005515976A5 (https=) | ||
| JP2003513075A5 (https=) |